相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
Howard Hochster et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials
Liat Vidal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Monoclonal anti body-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
Kenneth R. Carson et al.
LANCET ONCOLOGY (2009)
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Gilles Salles et al.
BLOOD (2008)
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma:: An East German Study Group hematology and oncology study
Michael Herold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rituximab maintenance therapy: a step forward in follicular lymphoma
Marinus H. J. van Oers
HAEMATOLOGICA (2007)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab
GB Fogarty et al.
CLINICAL ONCOLOGY (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Tolerability and safety of rituximab (MabThera®)
E Kimby
CANCER TREATMENT REVIEWS (2005)
Single agent rituximab in patients with follicular or mantle cell lymphoma:: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system:: a study of the Swiss Group for Clinical Cancer Research (SAKK)
A Ghielmini et al.
ANNALS OF ONCOLOGY (2005)
Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders
LN Gordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the minnie pearl cancer research network
JD Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
R Marcus et al.
BLOOD (2005)
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
R Forstpointner et al.
BLOOD (2004)
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly X 4 schedule
M Ghielmini et al.
BLOOD (2004)
分享论文
